ClinicalTrials.gg
CompletedNCT05565638PROFASTUpdated Oct 7, 2026Results posted

PROFAST Intervention in Precursor Multiple Myeloma

An interventional study of Prolonged Fasting Intervention and EDUCATION CONTROL in Cancer Prevention, Weight Loss and Smoldering Waldenstrom Macroglobulinemia(WM), sponsored by Dana-Farber Cancer Institute. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-07.

Primary conditionFastingRegistry: Weight LossReclassifiedWhy we changed it
Registry
Weight Loss — the first condition term the registry derived for this study.
ClinicalTrials.gg
Fasting
Why
  1. Weight Loss is a broad heading, used only when no more specific condition is named.
  2. The study's listed conditions name Fasting.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Dana-Farber Cancer Institute · Not applicable, Interventional, and Prevention

How we know

Updated Oct 7, 2026Results postedStudy documents posted+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
23
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 95 studies in Fasting with a site in United States — 19 open to participants now, 23 under way, none of them phase 3. Fasting · United States.

Enrollment
63rd of 85
23 · median 39
Started
2023
with 4 others
No phase
59 of 95
13 open now
Registered
75th of 95
by date

Among the 95 studies in Fasting with a site in United States, this one is the 63rd largest by enrollment of the 85 interventional ones that give a count, is one of 5 that started in 2023, is one of 59 with no phase, and was the 75th registered.

Fasting

392 studies on the registry are indexed under Fasting; 63 are open to participants now.

Browse Fasting studies →

Open to participants now

19 of the 95 studies in Fasting with a site in United States are open now. Recruiting first, the newest first:

14 more — sign in →

All 19 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 45 Fasting studies recruiting now, 15 (33%) set no upper age limit and 24 (53%) stop at 75 or younger; 7 take children under 18; 20 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 95 studies in Fasting with a site in United States, or all of them as a file.
02

Study summary

This is a 4-month randomized trial of a prolonged nightly fasting intervention (PROFAST) in 40 overweight and obese individuals with monoclonal gammopathy of undetermined significance (MGUS), smoldering multiple myeloma (SMM), and smoldering waldenstrom macroglobulinemia (SWM). The purpose of this study is to understand if fasting for a prolonged period of time during the nighttime hours is a strategy to prevent overweight and obese individuals from developing blood cancer.

Participants will be randomized into the following two groups:

  • Group A: PROFAST intervention for 4 months
  • Group B: Healthy Lifestyle Control group for 4 months
Read the detailed description

The purpose of this research study is to learn if fasting for a prolonged period of time could be used in the future to help improve body composition and prevent blood cancer in overweight and obese individuals with MGUS, SMM, and SWM. Multiple myeloma is a cancer of the plasma cells, which is an important part of the immune system. Participants with active multiple myeloma generally require treatment. There are currently no approved therapies or prevention strategies for smoldering multiple myeloma or monoclonal gammopathy of undetermined significance.

The National Cancer Institute of the National Institutes of Health is supporting this research study by providing funding.

This research study is a 4-month randomized trial of prolonged nightly fasting (PROFAST). It is expected that about 40 people will take part in this research study. The total study duration is 4 months.

Participants in the study will be randomized, in equal numbers to either the nightly fasting intervention group or a control group.

  • The prolonged nightly fasting (PROFAST) intervention involves gradually working up to a 14-hour fast during the nighttime hours. Participants will be supported by means of calls with a health coach during the first 4 weeks of the study. Participants will also be asked to use a text messaging platform to record their first and last meal of the day, and will receive personalized feedback based on the meal times via the text messaging system. The text messaging system will be used throughout the duration of the study.
  • For participants randomized to the control group, an introductory session with a health coach and educational information will be provided. Participants will also receive one email and one text message per week with tips on healthy living during the 4 months of the study.
03

Conditions studied

  • Cancer Prevention
  • Weight Loss
  • Smoldering Waldenstrom Macroglobulinemia(WM)
  • MGUS
  • Fasting
  • Multiple Myeloma

Browse trials for

Keywords

  • Cancer prevention
  • Weight loss
  • Smoldering Waldenstrom Macroglobulinemia(WM)
  • MGUS
  • Smoldering Multiple Myeloma
  • Prolonged nightly fasting
  • Multiple Myeloma
04

In context

Fasting Reclassified

392 studies on the registry are indexed under Fasting; 63 are open to participants now.

This study's enrollment of 23 is below the median of 45 across 311 interventional studies indexed under Fasting.

Browse Fasting studies →

Lead sponsor

Dana-Farber Cancer Institute is the lead sponsor of 836 studies on the registry; 121 are open to participants now.

Of its 114 completed or terminated interventional studies of FDA-regulated products, 78 (68%) have results posted.

Compared within Fasting, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Weight Loss. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • >= 25 kg/m2
  • Documented diagnosis of MGUS or Smoldering MM(SMM) or Smoldering Waldenstrom Macroglobulinemia(WM) via EMR review. *note: please review case with PI or treating MD if diagnosis is uncertain.
  • At least 18 years of age
  • Currently fasting for \<14 hours per night, as assessed using 24-hour food recalls
  • Owns a cell phone and is comfortable sending and receiving text messages
  • Ability to understand and the willingness to sign a written document

Exclusion criteria

Exclusion Criteria:

  • Diagnosis of overt MM or WM
  • Patients diagnosed with another requiring active therapy
  • Clinical diagnosis of diabetes, which may increase the risk of hypoglycemia with a prolonged fast. Note: patients with diabetes may enroll with consent from MD that manages their clinical care.
  • Any other condition that, in the investigator's judgment, would contraindicate prolonged nightly fasting or otherwise interfere with participation in the trial, including night shift work, night eating syndrome, taking weight loss medication, or participation in another weight loss program
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

06

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
23 participants (actual)

Study arms

  • Experimental
    PROLONGED FASTING INTERVENTION

    The prolonged nightly fasting (PROFAST) intervention involves gradually working up to a 14-hour fast during the nighttime hours. Participants will be supported by means of calls with a health coach during the first 4 weeks of the study. Participants will also be asked to use a text messaging platform to record their first and last meal of the day, and will receive personalized feedback based on the meal times they record via the text messaging system. The text messaging system will be used throughout the duration of the study.

    Behavioral: Prolonged Fasting Intervention

  • Active comparator
    EDUCATION CONTROL

    For participants randomized to the control group, an introductory session with a health coach and educational information will be provided. Participants will also receive one email and one text message per week with tips on healthy living during the 4 months of the study

    Behavioral: EDUCATION CONTROL

Interventions

  • BehavioralProlonged Fasting Intervention

    promote a 14-hour fast during the nighttime hours

  • BehavioralEDUCATION CONTROL

    introductory session with a health coach and educational information will be provided. Participants will also receive one email and one text message per week with tips on healthy living

07

What researchers measure

Primary outcomes

  1. Changes in Body Composition (% Body Fat)

    assessed via whole body DXA scans

    Time frame: baseline to 4-months

Secondary outcomes

  1. M-Protein Change by Serum Protein Electrophoresis and Serum Free Light Chain Assay

    Monoclonal (M-)proteins produced in excess by an abnormal clonal proliferation of plasma (MM) cells that can be measured in the serum using Serum Protein Electrophoresis (SPEP) and the Serum Free Light Chain Assay.

    Time frame: baseline to 4-months

  2. (M-)Protein Concentrations/Light Chains Change by Mass Spectrometry

    Time frame: Baseline to 4-months

  3. Changes in Bone Marrow Adiposity

    Time frame: Baseline to 4-months

  4. Changes in Plasma Metabolites Measured by Liquid Chromatography-mass Spectrometry

    Time frame: Baseline to 4-months

08

Results

Posted Oct 7, 2026

Participant flow

Participant flow — Overall Study
MilestonePROLONGED FASTING INTERVENTIONEDUCATION CONTROL
Started1112
Completed1010
Not completed12

Outcome measures

PrimaryChanges in Body Composition (% Body Fat)

assessed via whole body DXA scans

Time frame:
baseline to 4-months
Reported as:
Mean · Mean Raw Change % Fat
Changes in Body Composition (% Body Fat)
Mean Raw Change % FatPROLONGED FASTING INTERVENTIONEDUCATION CONTROL
Changes in Body Composition (% Body Fat)-1.62 ± 2.42-0.59 ± 2.30
SecondaryM-Protein Change by Serum Protein Electrophoresis and Serum Free Light Chain Assay

Monoclonal (M-)proteins produced in excess by an abnormal clonal proliferation of plasma (MM) cells that can be measured in the serum using Serum Protein Electrophoresis (SPEP) and the Serum Free Light Chain Assay.

Time frame:
baseline to 4-months

Results for this outcome have not been posted.

Secondary(M-)Protein Concentrations/Light Chains Change by Mass Spectrometry
Time frame:
Baseline to 4-months

Results for this outcome have not been posted.

SecondaryChanges in Bone Marrow Adiposity
Time frame:
Baseline to 4-months

Results for this outcome have not been posted.

SecondaryChanges in Plasma Metabolites Measured by Liquid Chromatography-mass Spectrometry
Time frame:
Baseline to 4-months

Results for this outcome have not been posted.

Adverse events

Collected over 4 months. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
PROLONGED FASTING INTERVENTION0/11 (0%)0/11 (0%)0/11 (0%)
EDUCATION CONTROL0/12 (0%)0/12 (0%)0/12 (0%)

Baseline characteristics

Age, Continuous
Age, Continuous(years)PROLONGED FASTING INTERVENTIONEDUCATION CONTROLTotal
Mean68.2 (51.8 to 84.4)65.6 (49.8 to 77.4)66.9 (49.8 to 84.4)
Sex: Female, Male
Sex: Female, Male(Participants)PROLONGED FASTING INTERVENTIONEDUCATION CONTROLTotal
Female358
Male8715
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)PROLONGED FASTING INTERVENTIONEDUCATION CONTROLTotal
Race (white) — White101020
Race (white) — Missing123
09

Study locations

1 site
  • Dana Farber Cancer Institute
    Boston, Massachusetts 02115, United States
10

References and documents

Publications

  • Lee DJ, O'Donnell EK, Raje N, Panaroni C, Redd R, Ligibel J, Sears DD, Nadeem O, Ghobrial IM, Marinac CR. Design and Rationale of Prolonged Nightly Fasting for Multiple Myeloma Prevention (PROFAST): Protocol for a Randomized Controlled Pilot Trial. JMIR Res Protoc. 2024 Mar 11;13:e51368. doi: 10.2196/51368. PubMed 38466984 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Undecided

11

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2023 to primary completion in Aug 2025, 28 months.

Results were first posted in Oct 2026, 1 year 2 months after primary completion.

Of 144 non-industry interventional studies with no phase under Fasting, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 40. This study's 28 months is above that.

Counting every sponsor, half of 149 studies reached it within 19 months; a quarter within 6 and three quarters within 40.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 22, 2022
First posted
Oct 4, 2022
StartActual
Mar 6, 2023
Primary completionActual
Aug 4, 2025
CompletionActual
Aug 4, 2025
Results first posted
Oct 7, 2026
Last update
Oct 7, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Results posted
posted Oct 7, 2026
Primary outcomes
1 edited
What changed in the outcomes
  • EditedChanges in body compositionBody Composition (% Body Fat)Time frame: baseline to 4-months
Oct 7, 2026
Secondary outcomes
4 edited
What changed in the outcomes
  • EditedM-Protein changeChange by Serum Protein Electrophoresis and Serum Free Light Chain assayAssayTime frame: baseline to 4-months
  • Edited(M-)protein concentrationsProtein Concentrations/light chains changeLight Chains Change by mass spectrometryMass SpectrometryTime frame: Baseline to 4-months
  • EditedChanges in bone marrow adiposityBone Marrow AdiposityTime frame: Baseline to 4-months
  • EditedChanges in plasma metabolites measuredPlasma Metabolites Measured by liquid chromatographyLiquid Chromatography-mass spectrometrySpectrometryTime frame: Baseline to 4-months
Oct 7, 2026
Show all 1 update
  1. Oct 7, 2026
    Results posted
    Primary outcomes 1 edited
    What changed in the outcomes
    • EditedChanges in body compositionBody Composition (% Body Fat)Time frame: baseline to 4-months
    Secondary outcomes 4 edited
    What changed in the outcomes
    • EditedM-Protein changeChange by Serum Protein Electrophoresis and Serum Free Light Chain assayAssayTime frame: baseline to 4-months
    • Edited(M-)protein concentrationsProtein Concentrations/light chains changeLight Chains Change by mass spectrometryMass SpectrometryTime frame: Baseline to 4-months
    • EditedChanges in bone marrow adiposityBone Marrow AdiposityTime frame: Baseline to 4-months
    • EditedChanges in plasma metabolites measuredPlasma Metabolites Measured by liquid chromatographyLiquid Chromatography-mass spectrometrySpectrometryTime frame: Baseline to 4-months
    + 3 other changes: verification date, oversight details and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

12

Registry details

Key details

Study ID
NCT05565638
Responsible party
Catherine Marinac, PhD (Principal Investigator, Dana-Farber Cancer Institute) — Principal investigator
First posted
Oct 4, 2022
Start date
Mar 6, 2023
Primary completion
Aug 4, 2025
Completion
Aug 4, 2025
Results posted
Oct 7, 2026
Last update
Oct 7, 2026

Study contacts

Catherine Marinac, Ph.D
principal investigator · Dana-Farber Cancer Institute

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion